nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—SLC22A3—Irinotecan—pancreatic cancer	0.102	0.13	CbGbCtD
Prazosin—ORM1—Erlotinib—pancreatic cancer	0.0805	0.103	CbGbCtD
Prazosin—CYP1A1—Dacarbazine—pancreatic cancer	0.0671	0.0857	CbGbCtD
Prazosin—ABCG2—Tamoxifen—pancreatic cancer	0.0578	0.0739	CbGbCtD
Prazosin—CYP1A1—Tamoxifen—pancreatic cancer	0.0533	0.0682	CbGbCtD
Prazosin—ABCG2—Erlotinib—pancreatic cancer	0.0491	0.0628	CbGbCtD
Prazosin—KCNH2—Sunitinib—pancreatic cancer	0.0468	0.0598	CbGbCtD
Prazosin—CYP1A1—Erlotinib—pancreatic cancer	0.0454	0.058	CbGbCtD
Prazosin—ABCG2—Irinotecan—pancreatic cancer	0.0444	0.0567	CbGbCtD
Prazosin—ABCG2—Fluorouracil—pancreatic cancer	0.0426	0.0544	CbGbCtD
Prazosin—ABCG2—Docetaxel—pancreatic cancer	0.0325	0.0416	CbGbCtD
Prazosin—ABCG2—Sunitinib—pancreatic cancer	0.0324	0.0414	CbGbCtD
Prazosin—ABCG2—Doxorubicin—pancreatic cancer	0.0242	0.031	CbGbCtD
Prazosin—ABCB1—Tamoxifen—pancreatic cancer	0.0208	0.0266	CbGbCtD
Prazosin—ABCB1—Gemcitabine—pancreatic cancer	0.018	0.023	CbGbCtD
Prazosin—ABCB1—Erlotinib—pancreatic cancer	0.0177	0.0227	CbGbCtD
Prazosin—ABCB1—Irinotecan—pancreatic cancer	0.016	0.0205	CbGbCtD
Prazosin—ABCB1—Docetaxel—pancreatic cancer	0.0117	0.015	CbGbCtD
Prazosin—ABCB1—Sunitinib—pancreatic cancer	0.0117	0.0149	CbGbCtD
Prazosin—ABCB1—Doxorubicin—pancreatic cancer	0.00874	0.0112	CbGbCtD
Prazosin—Fatigue—Tamoxifen—pancreatic cancer	0.000489	0.00422	CcSEcCtD
Prazosin—Oedema—Sunitinib—pancreatic cancer	0.000486	0.0042	CcSEcCtD
Prazosin—Pain—Tamoxifen—pancreatic cancer	0.000485	0.00419	CcSEcCtD
Prazosin—Constipation—Tamoxifen—pancreatic cancer	0.000485	0.00419	CcSEcCtD
Prazosin—Alopecia—Gemcitabine—pancreatic cancer	0.000485	0.00419	CcSEcCtD
Prazosin—Fatigue—Erlotinib—pancreatic cancer	0.000484	0.00418	CcSEcCtD
Prazosin—Pain—Erlotinib—pancreatic cancer	0.00048	0.00415	CcSEcCtD
Prazosin—Constipation—Erlotinib—pancreatic cancer	0.00048	0.00415	CcSEcCtD
Prazosin—Shock—Sunitinib—pancreatic cancer	0.000478	0.00413	CcSEcCtD
Prazosin—Alopecia—Fluorouracil—pancreatic cancer	0.000477	0.00412	CcSEcCtD
Prazosin—Angina pectoris—Docetaxel—pancreatic cancer	0.000474	0.00409	CcSEcCtD
Prazosin—Ill-defined disorder—Irinotecan—pancreatic cancer	0.000455	0.00393	CcSEcCtD
Prazosin—Urticaria—Tamoxifen—pancreatic cancer	0.000451	0.00389	CcSEcCtD
Prazosin—Body temperature increased—Erlotinib—pancreatic cancer	0.000444	0.00383	CcSEcCtD
Prazosin—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.000443	0.00383	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000443	0.00382	CcSEcCtD
Prazosin—Vision blurred—Fluorouracil—pancreatic cancer	0.000442	0.00382	CcSEcCtD
Prazosin—Malaise—Irinotecan—pancreatic cancer	0.000442	0.00382	CcSEcCtD
Prazosin—Vertigo—Irinotecan—pancreatic cancer	0.00044	0.00381	CcSEcCtD
Prazosin—Syncope—Irinotecan—pancreatic cancer	0.00044	0.0038	CcSEcCtD
Prazosin—Insomnia—Sunitinib—pancreatic cancer	0.000439	0.0038	CcSEcCtD
Prazosin—Paraesthesia—Sunitinib—pancreatic cancer	0.000436	0.00377	CcSEcCtD
Prazosin—Dyspnoea—Sunitinib—pancreatic cancer	0.000433	0.00374	CcSEcCtD
Prazosin—Loss of consciousness—Irinotecan—pancreatic cancer	0.000431	0.00372	CcSEcCtD
Prazosin—Malaise—Gemcitabine—pancreatic cancer	0.000431	0.00372	CcSEcCtD
Prazosin—Eye pain—Epirubicin—pancreatic cancer	0.00042	0.00363	CcSEcCtD
Prazosin—Fatigue—Sunitinib—pancreatic cancer	0.000419	0.00362	CcSEcCtD
Prazosin—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000418	0.00361	CcSEcCtD
Prazosin—Pain—Sunitinib—pancreatic cancer	0.000415	0.00359	CcSEcCtD
Prazosin—Constipation—Sunitinib—pancreatic cancer	0.000415	0.00359	CcSEcCtD
Prazosin—Discomfort—Irinotecan—pancreatic cancer	0.000412	0.00356	CcSEcCtD
Prazosin—Epistaxis—Docetaxel—pancreatic cancer	0.000409	0.00353	CcSEcCtD
Prazosin—Asthenia—Tamoxifen—pancreatic cancer	0.000407	0.00352	CcSEcCtD
Prazosin—Arthralgia—Gemcitabine—pancreatic cancer	0.000407	0.00351	CcSEcCtD
Prazosin—Asthenia—Erlotinib—pancreatic cancer	0.000403	0.00348	CcSEcCtD
Prazosin—Discomfort—Gemcitabine—pancreatic cancer	0.000402	0.00347	CcSEcCtD
Prazosin—Pruritus—Tamoxifen—pancreatic cancer	0.000401	0.00347	CcSEcCtD
Prazosin—Oedema—Irinotecan—pancreatic cancer	0.0004	0.00346	CcSEcCtD
Prazosin—Pruritus—Erlotinib—pancreatic cancer	0.000397	0.00343	CcSEcCtD
Prazosin—Discomfort—Fluorouracil—pancreatic cancer	0.000395	0.00341	CcSEcCtD
Prazosin—Shock—Irinotecan—pancreatic cancer	0.000394	0.0034	CcSEcCtD
Prazosin—Oedema—Gemcitabine—pancreatic cancer	0.00039	0.00337	CcSEcCtD
Prazosin—Eye pain—Doxorubicin—pancreatic cancer	0.000389	0.00336	CcSEcCtD
Prazosin—Diarrhoea—Tamoxifen—pancreatic cancer	0.000388	0.00335	CcSEcCtD
Prazosin—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000387	0.00334	CcSEcCtD
Prazosin—Body temperature increased—Sunitinib—pancreatic cancer	0.000384	0.00332	CcSEcCtD
Prazosin—Diarrhoea—Erlotinib—pancreatic cancer	0.000384	0.00332	CcSEcCtD
Prazosin—Oedema—Fluorouracil—pancreatic cancer	0.000383	0.00331	CcSEcCtD
Prazosin—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000377	0.00326	CcSEcCtD
Prazosin—Dizziness—Tamoxifen—pancreatic cancer	0.000375	0.00324	CcSEcCtD
Prazosin—Tachycardia—Fluorouracil—pancreatic cancer	0.000374	0.00323	CcSEcCtD
Prazosin—Dizziness—Erlotinib—pancreatic cancer	0.000371	0.00321	CcSEcCtD
Prazosin—Insomnia—Irinotecan—pancreatic cancer	0.000362	0.00313	CcSEcCtD
Prazosin—Flushing—Docetaxel—pancreatic cancer	0.000361	0.00312	CcSEcCtD
Prazosin—Vomiting—Tamoxifen—pancreatic cancer	0.000361	0.00312	CcSEcCtD
Prazosin—Paraesthesia—Irinotecan—pancreatic cancer	0.000359	0.0031	CcSEcCtD
Prazosin—Hypersensitivity—Sunitinib—pancreatic cancer	0.000358	0.00309	CcSEcCtD
Prazosin—Rash—Tamoxifen—pancreatic cancer	0.000358	0.00309	CcSEcCtD
Prazosin—Dermatitis—Tamoxifen—pancreatic cancer	0.000357	0.00309	CcSEcCtD
Prazosin—Vomiting—Erlotinib—pancreatic cancer	0.000357	0.00308	CcSEcCtD
Prazosin—Dyspnoea—Irinotecan—pancreatic cancer	0.000357	0.00308	CcSEcCtD
Prazosin—Somnolence—Irinotecan—pancreatic cancer	0.000356	0.00307	CcSEcCtD
Prazosin—Headache—Tamoxifen—pancreatic cancer	0.000355	0.00307	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000355	0.00307	CcSEcCtD
Prazosin—Rash—Erlotinib—pancreatic cancer	0.000354	0.00306	CcSEcCtD
Prazosin—Dermatitis—Erlotinib—pancreatic cancer	0.000353	0.00305	CcSEcCtD
Prazosin—Insomnia—Gemcitabine—pancreatic cancer	0.000352	0.00305	CcSEcCtD
Prazosin—Headache—Erlotinib—pancreatic cancer	0.000351	0.00304	CcSEcCtD
Prazosin—Paraesthesia—Gemcitabine—pancreatic cancer	0.00035	0.00302	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000349	0.00302	CcSEcCtD
Prazosin—Asthenia—Sunitinib—pancreatic cancer	0.000348	0.00301	CcSEcCtD
Prazosin—Dyspnoea—Gemcitabine—pancreatic cancer	0.000347	0.003	CcSEcCtD
Prazosin—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000347	0.003	CcSEcCtD
Prazosin—Insomnia—Fluorouracil—pancreatic cancer	0.000347	0.00299	CcSEcCtD
Prazosin—Somnolence—Gemcitabine—pancreatic cancer	0.000346	0.00299	CcSEcCtD
Prazosin—Fatigue—Irinotecan—pancreatic cancer	0.000345	0.00298	CcSEcCtD
Prazosin—Paraesthesia—Fluorouracil—pancreatic cancer	0.000344	0.00297	CcSEcCtD
Prazosin—Alopecia—Docetaxel—pancreatic cancer	0.000344	0.00297	CcSEcCtD
Prazosin—Pruritus—Sunitinib—pancreatic cancer	0.000344	0.00297	CcSEcCtD
Prazosin—Pain—Irinotecan—pancreatic cancer	0.000342	0.00296	CcSEcCtD
Prazosin—Constipation—Irinotecan—pancreatic cancer	0.000342	0.00296	CcSEcCtD
Prazosin—Dyspnoea—Fluorouracil—pancreatic cancer	0.000342	0.00295	CcSEcCtD
Prazosin—Somnolence—Fluorouracil—pancreatic cancer	0.000341	0.00294	CcSEcCtD
Prazosin—Nausea—Tamoxifen—pancreatic cancer	0.000337	0.00291	CcSEcCtD
Prazosin—Fatigue—Gemcitabine—pancreatic cancer	0.000336	0.0029	CcSEcCtD
Prazosin—Pain—Gemcitabine—pancreatic cancer	0.000333	0.00288	CcSEcCtD
Prazosin—Constipation—Gemcitabine—pancreatic cancer	0.000333	0.00288	CcSEcCtD
Prazosin—Nausea—Erlotinib—pancreatic cancer	0.000333	0.00288	CcSEcCtD
Prazosin—Diarrhoea—Sunitinib—pancreatic cancer	0.000332	0.00287	CcSEcCtD
Prazosin—Feeling abnormal—Irinotecan—pancreatic cancer	0.00033	0.00285	CcSEcCtD
Prazosin—Pain—Fluorouracil—pancreatic cancer	0.000328	0.00283	CcSEcCtD
Prazosin—Pancreatitis—Epirubicin—pancreatic cancer	0.000322	0.00278	CcSEcCtD
Prazosin—Dizziness—Sunitinib—pancreatic cancer	0.000321	0.00278	CcSEcCtD
Prazosin—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000321	0.00277	CcSEcCtD
Prazosin—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000321	0.00277	CcSEcCtD
Prazosin—Angina pectoris—Epirubicin—pancreatic cancer	0.00032	0.00276	CcSEcCtD
Prazosin—Body temperature increased—Irinotecan—pancreatic cancer	0.000316	0.00273	CcSEcCtD
Prazosin—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000316	0.00273	CcSEcCtD
Prazosin—Vomiting—Sunitinib—pancreatic cancer	0.000309	0.00267	CcSEcCtD
Prazosin—Body temperature increased—Gemcitabine—pancreatic cancer	0.000308	0.00266	CcSEcCtD
Prazosin—Rash—Sunitinib—pancreatic cancer	0.000306	0.00265	CcSEcCtD
Prazosin—Dermatitis—Sunitinib—pancreatic cancer	0.000306	0.00264	CcSEcCtD
Prazosin—Urticaria—Fluorouracil—pancreatic cancer	0.000304	0.00263	CcSEcCtD
Prazosin—Headache—Sunitinib—pancreatic cancer	0.000304	0.00263	CcSEcCtD
Prazosin—Syncope—Docetaxel—pancreatic cancer	0.000304	0.00263	CcSEcCtD
Prazosin—Pollakiuria—Epirubicin—pancreatic cancer	0.000303	0.00262	CcSEcCtD
Prazosin—Body temperature increased—Fluorouracil—pancreatic cancer	0.000303	0.00262	CcSEcCtD
Prazosin—Palpitations—Docetaxel—pancreatic cancer	0.000299	0.00259	CcSEcCtD
Prazosin—Loss of consciousness—Docetaxel—pancreatic cancer	0.000298	0.00257	CcSEcCtD
Prazosin—Pancreatitis—Doxorubicin—pancreatic cancer	0.000298	0.00257	CcSEcCtD
Prazosin—Angina pectoris—Doxorubicin—pancreatic cancer	0.000296	0.00255	CcSEcCtD
Prazosin—Hypersensitivity—Irinotecan—pancreatic cancer	0.000295	0.00255	CcSEcCtD
Prazosin—Drowsiness—Epirubicin—pancreatic cancer	0.000292	0.00253	CcSEcCtD
Prazosin—Arthralgia—Docetaxel—pancreatic cancer	0.000289	0.00249	CcSEcCtD
Prazosin—Nausea—Sunitinib—pancreatic cancer	0.000289	0.00249	CcSEcCtD
Prazosin—Asthenia—Irinotecan—pancreatic cancer	0.000287	0.00248	CcSEcCtD
Prazosin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000282	0.00244	CcSEcCtD
Prazosin—Dry mouth—Docetaxel—pancreatic cancer	0.000282	0.00244	CcSEcCtD
Prazosin—Pollakiuria—Doxorubicin—pancreatic cancer	0.00028	0.00242	CcSEcCtD
Prazosin—Asthenia—Gemcitabine—pancreatic cancer	0.00028	0.00242	CcSEcCtD
Prazosin—Oedema—Docetaxel—pancreatic cancer	0.000277	0.00239	CcSEcCtD
Prazosin—Epistaxis—Epirubicin—pancreatic cancer	0.000276	0.00238	CcSEcCtD
Prazosin—Pruritus—Gemcitabine—pancreatic cancer	0.000276	0.00238	CcSEcCtD
Prazosin—Diarrhoea—Irinotecan—pancreatic cancer	0.000274	0.00237	CcSEcCtD
Prazosin—Shock—Docetaxel—pancreatic cancer	0.000272	0.00235	CcSEcCtD
Prazosin—Pruritus—Fluorouracil—pancreatic cancer	0.000271	0.00234	CcSEcCtD
Prazosin—Drowsiness—Doxorubicin—pancreatic cancer	0.000271	0.00234	CcSEcCtD
Prazosin—Tachycardia—Docetaxel—pancreatic cancer	0.00027	0.00233	CcSEcCtD
Prazosin—Bradycardia—Epirubicin—pancreatic cancer	0.000267	0.00231	CcSEcCtD
Prazosin—Diarrhoea—Gemcitabine—pancreatic cancer	0.000267	0.0023	CcSEcCtD
Prazosin—Dizziness—Irinotecan—pancreatic cancer	0.000265	0.00229	CcSEcCtD
Prazosin—Diarrhoea—Fluorouracil—pancreatic cancer	0.000262	0.00227	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—pancreatic cancer	0.000255	0.00221	CcSEcCtD
Prazosin—Vomiting—Irinotecan—pancreatic cancer	0.000254	0.0022	CcSEcCtD
Prazosin—Dizziness—Fluorouracil—pancreatic cancer	0.000253	0.00219	CcSEcCtD
Prazosin—Rash—Irinotecan—pancreatic cancer	0.000252	0.00218	CcSEcCtD
Prazosin—Dermatitis—Irinotecan—pancreatic cancer	0.000252	0.00218	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000252	0.00218	CcSEcCtD
Prazosin—Headache—Irinotecan—pancreatic cancer	0.000251	0.00217	CcSEcCtD
Prazosin—Insomnia—Docetaxel—pancreatic cancer	0.00025	0.00216	CcSEcCtD
Prazosin—Paraesthesia—Docetaxel—pancreatic cancer	0.000248	0.00215	CcSEcCtD
Prazosin—Vomiting—Gemcitabine—pancreatic cancer	0.000248	0.00214	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—pancreatic cancer	0.000247	0.00214	CcSEcCtD
Prazosin—Dyspnoea—Docetaxel—pancreatic cancer	0.000247	0.00213	CcSEcCtD
Prazosin—Somnolence—Docetaxel—pancreatic cancer	0.000246	0.00212	CcSEcCtD
Prazosin—Rash—Gemcitabine—pancreatic cancer	0.000246	0.00212	CcSEcCtD
Prazosin—Dermatitis—Gemcitabine—pancreatic cancer	0.000246	0.00212	CcSEcCtD
Prazosin—Tinnitus—Epirubicin—pancreatic cancer	0.000245	0.00212	CcSEcCtD
Prazosin—Headache—Gemcitabine—pancreatic cancer	0.000244	0.00211	CcSEcCtD
Prazosin—Flushing—Epirubicin—pancreatic cancer	0.000244	0.00211	CcSEcCtD
Prazosin—Vomiting—Fluorouracil—pancreatic cancer	0.000244	0.00211	CcSEcCtD
Prazosin—Rash—Fluorouracil—pancreatic cancer	0.000242	0.00209	CcSEcCtD
Prazosin—Dermatitis—Fluorouracil—pancreatic cancer	0.000241	0.00209	CcSEcCtD
Prazosin—Headache—Fluorouracil—pancreatic cancer	0.00024	0.00207	CcSEcCtD
Prazosin—Fatigue—Docetaxel—pancreatic cancer	0.000238	0.00206	CcSEcCtD
Prazosin—Nausea—Irinotecan—pancreatic cancer	0.000238	0.00205	CcSEcCtD
Prazosin—Pain—Docetaxel—pancreatic cancer	0.000237	0.00204	CcSEcCtD
Prazosin—Constipation—Docetaxel—pancreatic cancer	0.000237	0.00204	CcSEcCtD
Prazosin—Alopecia—Epirubicin—pancreatic cancer	0.000232	0.002	CcSEcCtD
Prazosin—Nausea—Gemcitabine—pancreatic cancer	0.000231	0.002	CcSEcCtD
Prazosin—Feeling abnormal—Docetaxel—pancreatic cancer	0.000228	0.00197	CcSEcCtD
Prazosin—Nausea—Fluorouracil—pancreatic cancer	0.000228	0.00197	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—pancreatic cancer	0.000227	0.00196	CcSEcCtD
Prazosin—Flushing—Doxorubicin—pancreatic cancer	0.000225	0.00195	CcSEcCtD
Prazosin—Tension—Epirubicin—pancreatic cancer	0.000224	0.00194	CcSEcCtD
Prazosin—Nervousness—Epirubicin—pancreatic cancer	0.000222	0.00192	CcSEcCtD
Prazosin—Body temperature increased—Docetaxel—pancreatic cancer	0.000219	0.00189	CcSEcCtD
Prazosin—Vision blurred—Epirubicin—pancreatic cancer	0.000215	0.00186	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—pancreatic cancer	0.000215	0.00186	CcSEcCtD
Prazosin—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000212	0.00183	CcSEcCtD
Prazosin—Tension—Doxorubicin—pancreatic cancer	0.000208	0.00179	CcSEcCtD
Prazosin—Malaise—Epirubicin—pancreatic cancer	0.000206	0.00178	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—pancreatic cancer	0.000205	0.00177	CcSEcCtD
Prazosin—Vertigo—Epirubicin—pancreatic cancer	0.000205	0.00177	CcSEcCtD
Prazosin—Syncope—Epirubicin—pancreatic cancer	0.000205	0.00177	CcSEcCtD
Prazosin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000204	0.00176	CcSEcCtD
Prazosin—Palpitations—Epirubicin—pancreatic cancer	0.000202	0.00175	CcSEcCtD
Prazosin—Loss of consciousness—Epirubicin—pancreatic cancer	0.000201	0.00174	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—pancreatic cancer	0.000199	0.00172	CcSEcCtD
Prazosin—Asthenia—Docetaxel—pancreatic cancer	0.000198	0.00171	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000196	0.0017	CcSEcCtD
Prazosin—Pruritus—Docetaxel—pancreatic cancer	0.000196	0.00169	CcSEcCtD
Prazosin—Arthralgia—Epirubicin—pancreatic cancer	0.000195	0.00168	CcSEcCtD
Prazosin—Discomfort—Epirubicin—pancreatic cancer	0.000192	0.00166	CcSEcCtD
Prazosin—Malaise—Doxorubicin—pancreatic cancer	0.000191	0.00165	CcSEcCtD
Prazosin—Dry mouth—Epirubicin—pancreatic cancer	0.00019	0.00164	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—pancreatic cancer	0.00019	0.00164	CcSEcCtD
Prazosin—Syncope—Doxorubicin—pancreatic cancer	0.00019	0.00164	CcSEcCtD
Prazosin—Diarrhoea—Docetaxel—pancreatic cancer	0.000189	0.00164	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—pancreatic cancer	0.000187	0.00161	CcSEcCtD
Prazosin—Oedema—Epirubicin—pancreatic cancer	0.000187	0.00161	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000186	0.00161	CcSEcCtD
Prazosin—Shock—Epirubicin—pancreatic cancer	0.000184	0.00159	CcSEcCtD
Prazosin—Dizziness—Docetaxel—pancreatic cancer	0.000183	0.00158	CcSEcCtD
Prazosin—Tachycardia—Epirubicin—pancreatic cancer	0.000182	0.00157	CcSEcCtD
Prazosin—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00018	0.00156	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—pancreatic cancer	0.00018	0.00156	CcSEcCtD
Prazosin—Discomfort—Doxorubicin—pancreatic cancer	0.000178	0.00154	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—pancreatic cancer	0.000176	0.00152	CcSEcCtD
Prazosin—Vomiting—Docetaxel—pancreatic cancer	0.000176	0.00152	CcSEcCtD
Prazosin—Rash—Docetaxel—pancreatic cancer	0.000174	0.00151	CcSEcCtD
Prazosin—Dermatitis—Docetaxel—pancreatic cancer	0.000174	0.00151	CcSEcCtD
Prazosin—Headache—Docetaxel—pancreatic cancer	0.000173	0.0015	CcSEcCtD
Prazosin—Oedema—Doxorubicin—pancreatic cancer	0.000173	0.00149	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00017	0.00147	CcSEcCtD
Prazosin—Shock—Doxorubicin—pancreatic cancer	0.00017	0.00147	CcSEcCtD
Prazosin—Insomnia—Epirubicin—pancreatic cancer	0.000169	0.00146	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—pancreatic cancer	0.000168	0.00146	CcSEcCtD
Prazosin—Paraesthesia—Epirubicin—pancreatic cancer	0.000168	0.00145	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000167	0.00144	CcSEcCtD
Prazosin—Dyspnoea—Epirubicin—pancreatic cancer	0.000166	0.00144	CcSEcCtD
Prazosin—Somnolence—Epirubicin—pancreatic cancer	0.000166	0.00143	CcSEcCtD
Prazosin—Nausea—Docetaxel—pancreatic cancer	0.000164	0.00142	CcSEcCtD
Prazosin—Fatigue—Epirubicin—pancreatic cancer	0.000161	0.00139	CcSEcCtD
Prazosin—Constipation—Epirubicin—pancreatic cancer	0.00016	0.00138	CcSEcCtD
Prazosin—Pain—Epirubicin—pancreatic cancer	0.00016	0.00138	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000157	0.00136	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—pancreatic cancer	0.000156	0.00135	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—pancreatic cancer	0.000155	0.00134	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—pancreatic cancer	0.000154	0.00133	CcSEcCtD
Prazosin—Feeling abnormal—Epirubicin—pancreatic cancer	0.000154	0.00133	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—pancreatic cancer	0.000153	0.00133	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—pancreatic cancer	0.000149	0.00129	CcSEcCtD
Prazosin—Urticaria—Epirubicin—pancreatic cancer	0.000148	0.00128	CcSEcCtD
Prazosin—Constipation—Doxorubicin—pancreatic cancer	0.000148	0.00128	CcSEcCtD
Prazosin—Pain—Doxorubicin—pancreatic cancer	0.000148	0.00128	CcSEcCtD
Prazosin—Body temperature increased—Epirubicin—pancreatic cancer	0.000147	0.00127	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000142	0.00123	CcSEcCtD
Prazosin—Hypersensitivity—Epirubicin—pancreatic cancer	0.000137	0.00119	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—pancreatic cancer	0.000137	0.00118	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—pancreatic cancer	0.000136	0.00118	CcSEcCtD
Prazosin—Asthenia—Epirubicin—pancreatic cancer	0.000134	0.00116	CcSEcCtD
Prazosin—Pruritus—Epirubicin—pancreatic cancer	0.000132	0.00114	CcSEcCtD
Prazosin—Diarrhoea—Epirubicin—pancreatic cancer	0.000128	0.0011	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000127	0.0011	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—pancreatic cancer	0.000124	0.00107	CcSEcCtD
Prazosin—Dizziness—Epirubicin—pancreatic cancer	0.000123	0.00107	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—pancreatic cancer	0.000122	0.00106	CcSEcCtD
Prazosin—Vomiting—Epirubicin—pancreatic cancer	0.000119	0.00102	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—pancreatic cancer	0.000118	0.00102	CcSEcCtD
Prazosin—Rash—Epirubicin—pancreatic cancer	0.000118	0.00102	CcSEcCtD
Prazosin—Dermatitis—Epirubicin—pancreatic cancer	0.000118	0.00102	CcSEcCtD
Prazosin—Headache—Epirubicin—pancreatic cancer	0.000117	0.00101	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—pancreatic cancer	0.000114	0.000986	CcSEcCtD
Prazosin—Nausea—Epirubicin—pancreatic cancer	0.000111	0.000957	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—pancreatic cancer	0.00011	0.000948	CcSEcCtD
Prazosin—Rash—Doxorubicin—pancreatic cancer	0.000109	0.00094	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—pancreatic cancer	0.000109	0.000939	CcSEcCtD
Prazosin—Headache—Doxorubicin—pancreatic cancer	0.000108	0.000934	CcSEcCtD
Prazosin—Nausea—Doxorubicin—pancreatic cancer	0.000103	0.000886	CcSEcCtD
Prazosin—ADRA1B—Signaling Pathways—NFKBIA—pancreatic cancer	9.55e-06	9.36e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—HRAS—pancreatic cancer	9.52e-06	9.34e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	9.51e-06	9.33e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	9.47e-06	9.28e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NOTCH1—pancreatic cancer	9.46e-06	9.27e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	9.32e-06	9.14e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	9.3e-06	9.12e-05	CbGpPWpGaD
Prazosin—HTR1D—GPCR downstream signaling—AKT1—pancreatic cancer	9.26e-06	9.08e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	9.25e-06	9.07e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	9.25e-06	9.07e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CASP3—pancreatic cancer	9.18e-06	9e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—EGFR—pancreatic cancer	9.17e-06	8.99e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	9.14e-06	8.96e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	9.13e-06	8.95e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	9.1e-06	8.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	9.06e-06	8.88e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CB—pancreatic cancer	8.95e-06	8.77e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CCND1—pancreatic cancer	8.93e-06	8.76e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	8.92e-06	8.74e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTGS2—pancreatic cancer	8.86e-06	8.69e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	8.85e-06	8.68e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	8.85e-06	8.68e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CTNNB1—pancreatic cancer	8.84e-06	8.67e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CD—pancreatic cancer	8.84e-06	8.67e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—PIK3CA—pancreatic cancer	8.81e-06	8.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PPARG—pancreatic cancer	8.81e-06	8.64e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTGS2—pancreatic cancer	8.77e-06	8.6e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.76e-06	8.59e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—APOE—pancreatic cancer	8.76e-06	8.59e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MMP9—pancreatic cancer	8.67e-06	8.5e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	8.66e-06	8.5e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—KRAS—pancreatic cancer	8.66e-06	8.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	8.64e-06	8.47e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PTEN—pancreatic cancer	8.62e-06	8.45e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—PIK3CA—pancreatic cancer	8.6e-06	8.44e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—TYMS—pancreatic cancer	8.6e-06	8.43e-05	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—AKT1—pancreatic cancer	8.59e-06	8.42e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CB—pancreatic cancer	8.54e-06	8.37e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	8.54e-06	8.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	8.48e-06	8.32e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	8.46e-06	8.29e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.46e-06	8.29e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	8.43e-06	8.26e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—AKT1—pancreatic cancer	8.41e-06	8.25e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	8.4e-06	8.24e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	8.36e-06	8.2e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.29e-06	8.13e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	8.29e-06	8.12e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	8.25e-06	8.09e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	8.21e-06	8.05e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	8.21e-06	8.05e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CXCL8—pancreatic cancer	8.2e-06	8.05e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTGS2—pancreatic cancer	8.18e-06	8.02e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—HRAS—pancreatic cancer	8.15e-06	7.99e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	8.13e-06	7.97e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	8.12e-06	7.96e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.05e-06	7.9e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	8.02e-06	7.87e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—SRC—pancreatic cancer	7.99e-06	7.84e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	7.96e-06	7.8e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—PIK3CA—pancreatic cancer	7.95e-06	7.8e-05	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—AKT1—pancreatic cancer	7.93e-06	7.77e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	7.9e-06	7.75e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	7.88e-06	7.73e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CASP3—pancreatic cancer	7.85e-06	7.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	7.8e-06	7.65e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—VEGFA—pancreatic cancer	7.79e-06	7.63e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTEN—pancreatic cancer	7.73e-06	7.58e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—pancreatic cancer	7.71e-06	7.56e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CB—pancreatic cancer	7.71e-06	7.56e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NRAS—pancreatic cancer	7.69e-06	7.54e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	7.68e-06	7.53e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—pancreatic cancer	7.65e-06	7.5e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—pancreatic cancer	7.64e-06	7.5e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	7.63e-06	7.48e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	7.63e-06	7.48e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PPARG—pancreatic cancer	7.63e-06	7.48e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CTNNB1—pancreatic cancer	7.57e-06	7.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	7.54e-06	7.4e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	7.48e-06	7.34e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	7.44e-06	7.3e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—pancreatic cancer	7.42e-06	7.28e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	7.41e-06	7.26e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—pancreatic cancer	7.38e-06	7.23e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	7.36e-06	7.22e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	7.31e-06	7.17e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	7.22e-06	7.08e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—pancreatic cancer	7.2e-06	7.06e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—pancreatic cancer	7.16e-06	7.02e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	7.16e-06	7.02e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.15e-06	7.01e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	7.15e-06	7.01e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TGFB1—pancreatic cancer	7.15e-06	7.01e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—pancreatic cancer	7.13e-06	6.99e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	7.1e-06	6.97e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	7.09e-06	6.95e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	7.09e-06	6.95e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	7.07e-06	6.93e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—pancreatic cancer	7.03e-06	6.89e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	7.01e-06	6.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	6.99e-06	6.86e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—APOE—pancreatic cancer	6.99e-06	6.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	6.95e-06	6.82e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	6.95e-06	6.81e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—pancreatic cancer	6.93e-06	6.8e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	6.91e-06	6.77e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	6.9e-06	6.77e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	6.84e-06	6.71e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	6.84e-06	6.71e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	6.83e-06	6.7e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	6.81e-06	6.68e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	6.77e-06	6.63e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	6.71e-06	6.58e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	6.7e-06	6.57e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	6.66e-06	6.53e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	6.66e-06	6.53e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	6.66e-06	6.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.65e-06	6.52e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	6.62e-06	6.49e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	6.6e-06	6.47e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	6.6e-06	6.47e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	6.58e-06	6.45e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	6.58e-06	6.45e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	6.57e-06	6.44e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	6.52e-06	6.39e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	6.5e-06	6.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.5e-06	6.37e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	6.47e-06	6.34e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	6.43e-06	6.3e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	6.34e-06	6.22e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—pancreatic cancer	6.31e-06	6.19e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	6.29e-06	6.17e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	6.28e-06	6.16e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	6.27e-06	6.15e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	6.18e-06	6.06e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	6.16e-06	6.04e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	6.13e-06	6.01e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	6.12e-06	6e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	6.12e-06	6e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PPARG—pancreatic cancer	6.09e-06	5.97e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	6.08e-06	5.96e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	6.06e-06	5.94e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	6.05e-06	5.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—pancreatic cancer	6.04e-06	5.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.04e-06	5.92e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	6.02e-06	5.9e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	6.01e-06	5.89e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—pancreatic cancer	6e-06	5.88e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	6e-06	5.88e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	5.97e-06	5.86e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SRC—pancreatic cancer	5.96e-06	5.85e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	5.96e-06	5.84e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	5.94e-06	5.83e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—pancreatic cancer	5.88e-06	5.77e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	5.85e-06	5.73e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	5.84e-06	5.73e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	5.81e-06	5.69e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	5.79e-06	5.68e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	5.75e-06	5.64e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	5.74e-06	5.63e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	5.68e-06	5.57e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	5.67e-06	5.56e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	5.64e-06	5.53e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	5.63e-06	5.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	5.62e-06	5.51e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	5.58e-06	5.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	5.58e-06	5.47e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.55e-06	5.44e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	5.54e-06	5.43e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	5.53e-06	5.42e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	5.52e-06	5.41e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	5.48e-06	5.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	5.47e-06	5.36e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	5.46e-06	5.36e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—pancreatic cancer	5.45e-06	5.35e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	5.44e-06	5.33e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	5.43e-06	5.32e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	5.41e-06	5.31e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	5.4e-06	5.29e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	5.38e-06	5.27e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—pancreatic cancer	5.34e-06	5.24e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	5.33e-06	5.23e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	5.31e-06	5.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	5.24e-06	5.13e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—pancreatic cancer	5.23e-06	5.13e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	5.23e-06	5.12e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	5.2e-06	5.1e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	5.19e-06	5.08e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	5.11e-06	5.02e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	5.09e-06	4.99e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	5.08e-06	4.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	5.08e-06	4.98e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	5.05e-06	4.96e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	5.04e-06	4.95e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	5.04e-06	4.94e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	5.03e-06	4.93e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	4.98e-06	4.88e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	4.97e-06	4.87e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	4.94e-06	4.84e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	4.93e-06	4.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	4.91e-06	4.82e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	4.86e-06	4.77e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	4.85e-06	4.76e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.84e-06	4.74e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	4.82e-06	4.72e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.79e-06	4.7e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	4.7e-06	4.61e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.7e-06	4.61e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	4.69e-06	4.6e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	4.56e-06	4.48e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	4.55e-06	4.46e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	4.54e-06	4.45e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	4.52e-06	4.43e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	4.52e-06	4.43e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	4.51e-06	4.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	4.51e-06	4.42e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—pancreatic cancer	4.45e-06	4.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	4.42e-06	4.34e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—pancreatic cancer	4.41e-06	4.32e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—pancreatic cancer	4.39e-06	4.3e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	4.35e-06	4.26e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	4.32e-06	4.24e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	4.26e-06	4.18e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	4.25e-06	4.17e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	4.2e-06	4.12e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	4.2e-06	4.12e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	4.19e-06	4.11e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—pancreatic cancer	4.18e-06	4.1e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	4.18e-06	4.1e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	4.18e-06	4.1e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—pancreatic cancer	4.11e-06	4.03e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	4.11e-06	4.03e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	4e-06	3.92e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	3.88e-06	3.81e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	3.84e-06	3.76e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.84e-06	3.76e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	3.71e-06	3.64e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	3.71e-06	3.63e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	3.69e-06	3.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.57e-06	3.5e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	3.55e-06	3.48e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	3.53e-06	3.46e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—pancreatic cancer	3.48e-06	3.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	3.45e-06	3.38e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	3.3e-06	3.23e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	3.13e-06	3.07e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—pancreatic cancer	3.02e-06	2.96e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.95e-06	2.89e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.91e-06	2.86e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—pancreatic cancer	2.41e-06	2.36e-05	CbGpPWpGaD
